Conference Call and Webcast Information:
| Date: | |
| Time: | |
| Dial-in: | 1-877-407-9208 (U.S. Investors) 1-201-493-6784 (International) |
| Conference I.D.: | 13762779 |
| CallMeTM: | Click Here |
| Webcast: | Click Here |
A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call.
ProMIS has also published an investor Q&A outlining the scientific rationale that differentiates PMN310 from other amyloid-targeting approaches, available in the Investors section of the ProMIS website: PMN310 Scientific and Clinical Update (
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AßOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact
Carie Pierce
VP Investor Relations & External Affairs
IR@ProMISNeurosciences.com
Media Contact
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
For further information:
Visit us at www.promisneurosciences.com
